Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 19, Number 3—March 2013

Effects of Vaccine Program against Pandemic Influenza A(H1N1) Virus, United States, 2009–2010

Rebekah H. Borse1, Sundar S. Shrestha, Anthony E. Fiore, Charisma Y. Atkins, James A. Singleton, Carolyn Furlow, and Martin I. MeltzerComments to Author 
Author affiliations: Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table 6

Sensitivity analysis showing number of clinical cases prevented by vaccination against influenza A(H1N1)pdm09 virus for different scenarios of vaccine distribution*

Subgroup Base case estimate
 (range)† Scenario
1: even distribution over time (range)‡ 2: distribution based on population proportion (range)§ 3: 2008 distribution (range)¶ 4: ACIP priority subgroups (range)#
6 mo–9 y 81,518
 (52,081–100,349) 131,170 
(90,932–164,352) 57,511
 (39,869–72,060) 65,093
 (45,125–81,559) 186,041
10–24 y (10–17 all, 18–24 NP) 300,724
 (212,953–420,991) 279,715
 (196,606–392,577) 310,656
 (218,355–436,003) 249,981
 (175,708–350,847) 396,725
Pregnant, 18–64 y 71,601
 (53,084–97,884) 44,486
 (31,726–60,936) 30,506
 (21,756–41,787) 14,809
 (10,561–20,285) 63,096
HR, 25–64 y 164,958
 (116,575–228,593) 168,521
 (119,243–233,197) 183,417
 (129,784–253,810) 73,157
 (51,765–101,234) 239,017
HCW, 25–64 y 123,427
 (87,287–177,144) 100,229
 (69,407–144,610) 82,764
 (57,313–119,413) 41,099
 (28,460–59,297) 142,157 
Contact with <6 mo 29,063
 (19,904–43,129) 28,861
 (19,686–42,794) 37,583
 (25,634–55,726) 151,525 
(103,351–224,675) 40,935
25–64 y (all others) 163,327
 (107,305–248,548) 197,372 
(133,316–297,625) 366,354
 (247,455–552,439) 278,226
 (187,928–419,547) 0
>65 y
1,067,971 (748,306–1,472,881)

Assumed % distribution by week**
6 mo–9 y, 1st dose†† 20 20 9 10 28
6 mo–9 y, 2nd dose 10 10 4 5 14
10–24 y (10–17 all, 18–24 NP) 18 18 20 16 25
Pregnant, 18–64 y 3 3 2 1 4
HR, 25–64 y 10 10 11 5 15
HCW, 25–64 y 7 7 6 3 10
Contact with <6 mo 2 2 3 12 3
25–64 y (all others) 17 17 32 24 0
>65 y 12 12 13 24 0

*Data reflect calculations made in scenarios 1 –4. ACIP, Advisory Committee on Immunization Practices; NP, not pregnant; HR, high risk; HCW, health care worker; contact, household contacts and caregivers of children <6 mo of age.
†Total number of doses administered to each population subgroup (Table 2).
‡For each population subgroup, this scenario assumes that the group received the same proportion of the total number of doses; the proportions were applied to the total number of doses administered each week (Table 2, Appendix).
§ It was assumed that the distribution of vaccines was proportional to the population.
¶Distribution of vaccine was based on estimates of estimated 2008 seasonal vaccine uptake (17,38).
#Distribution of vaccine was based exclusively on ACIP priority groupings. The proportion of doses administered was based on the proportion of doses administered to persons in each of the subgroups during the A(H1N1)pdm09 virus vaccination program, while excluding the non ACIP subgroups.
**In scenarios 1–4, the epidemiologic curve was based on the estimated A(H1N1)pdm09 vaccination curve, for which no vaccination program was assumed (Figure 1). We also assumed that the total number of vaccines administered each week remained exactly the same as outlined in Table 2, Appendix.
††For scenarios 1–4, we assumed that the 6 mo– 9 y age group required 2 doses and that a 4 wk delay was required between the first and second dose. We also assumed that no children 6 mo–9 years of age could have received their second dose until the fifth week of the vaccination program. Therefore, any doses during the first 4 wk that would have been proportioned as a second dose were added as a first dose.

Main Article

  1. Department of Homeland Security. Press briefing on swine influenza with Department of Homeland Security and Counterterrorism, Centers for Disease Control and Prevention, and the White House. Washington: Office of the Press Secretary; 2009 April 26 [cited 2011 Mar 30].
  2. Shrestha  SS, Swerdlow  DL, Borse  RH, Prabhu  VS, Finelli  L, Atkins  CY, Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009–April 2010). Clin Infect Dis. 2011;52(Suppl 1):S7582 . DOIPubMed
  3. US Food and Drug Administration. FDA approves vaccines for 2009 H1N1 influenza virus—approval provides important tool to fight pandemic. 2009 Sep 15 [cited 2010 Mar 20].
  4. Centers for Disease Control and Prevention. Interim results: state-specific influenza A (H1N1) 2009 monovalent vaccination coverage—United States, October 2009–January 2010. MMWR Morb Mortal Wkly Rep. 2010;59:3638 .PubMed
  5. Schuchat  A, Bell  BP, Redd  SC. The science behind preparing and responding to pandemic influenza: the lessons and limits of science. Clin Infect Dis. 2011;52(Suppl 1):S812. DOIPubMed
  6. Sypsa  V, Hatzakis  A. School closure is currently the main strategy to mitigate influenza A(H1N1)v: a modeling study. Euro Surveill. 2009;14:pii19240 .PubMed
  7. Partridge  J, Kieny  MP. World Health Organization H1N1 influenza vaccine Task Force. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009–2010 and comparison with previous estimates and global action plan targets. Vaccine. 2010;28:470912 . DOIPubMed
  8. US Food and Drug Administration, Vaccines and Related Biological Products Advisory Committee. Transcript of July 23, 2009 VRBPAC meeting. Regulatory consideration regarding the use of novel influenza A (H1N1) virus vaccines. 2010 [cited 2011 Mar 30].
  9. Centers for Disease Control and Prevention [Internet]. Influenza vaccination coverage, 2009–10 influenza season. 2011 [updated 2012 Sep 26; cited 2011 Mar 30].
  10. Singleton  JA. H1N1 vaccination coverage. Advisory Committee on Immunization Practices February 2010 meeting; presentation slides; 2010 Feb 25–26 meeting. Atlanta, Georgia. Atlanta: Centers for Disease Control and Prevention [cited 2011 Mar 30].
  11. Centers for Disease Control and Prevention. Final estimates for 2009–10 seasonal influenza and influenza A (H1N1) 2009 monovalent vaccination coverage—United States, August 2009 through May, 2010 [cited 2011 Feb 1].
  12. Veguilla  V, Hancock  K, Schiffer  J, Gargiullo  P, Lu  X, Aranio  D, Sensitivity and specificity of serologic assays for the detection of human infection with 2009 pandemic H1N1 virus in U.S. populations. J Clin Microbiol. 2011;49:22105. DOIPubMed
  13. Centers for Disease Control and Prevention. Updated CDC estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States, April 2009–April 10, 2010 [cited 2011 Mar 30].
  14. Singleton  JA. Who got H1N1 vaccine? Findings from the U.S. 2009–2010 influenza vaccination surveillance systems. 44th National Immunization Conference. Atlanta, GA, USA, 2010 April 22 [cited 2011 Mar 30].
  15. Wortley  P. H1N1 Influenza vaccination coverage by ACIP target groups, program implementation. 2010 [cited 2010 Apr 22].
  16. Centers for Disease and Prevention. Interim results: influenza A (H1N1) 2009 monovalent and seasonal influenza vaccination coverage among health-care personnel—United States, August 2009–January 2010. MMWR Morb Mortal Wkly Rep. 2010;59:35762 .PubMed
  17. Centers for Disease Control and Prevention. Projected influenza vaccination target population sizes, vaccination coverage and doses to be used during the 2008–09 season. 2008 [cited 2009 August 30].
  18. Moro  PL, Broder  K, Zheteyeva  Y, Revzina  N, Tepper  N, Kissin  D, Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. Am J Obstet Gynecol. 2011;205:473. DOIPubMed
  19. Jain  S, Kamimoto  L, Bramley  AM, Schmitz  AM, Benoit  SR, Louie  J, Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med. 2009;361:193544 . DOIPubMed
  20. Reed  C, Angulo  FJ, Swerdlow  DL, Lipsitch  M, Meltzer  MI, Jernigan  DB, Estimates of the prevalence of pandemic (H1N1) 2009, United States, April–July 2009. Emerg Infect Dis. 2009;15:20047 .DOIPubMed
  21. Skarbinski  J, Jain  S, Bramley  A, Lee  EJ, Huang  J, Kirschke  D, Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States—September–October 2009. Clin Infect Dis. 2011;52(Suppl 1):S509. DOIPubMed
  22. Furlow  CF, Singleton  JA, Bardenheier  B. Combining estimates of influenza vaccination coverage from the BRFSS 2009–2010 and the National 2009 H1N1 Flu Survey. Poster presented at: Annual Behavioral Risk Factor Surveillance System Conference; Atlanta, GA, USA; March 20–23, 2011.
  23. Centers for Disease Control and Prevention. Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep. 2009;58:11001 .PubMed
  24. Wu  J, Xu  F, Lu  L, Lu  M, Miao  L, Gao  T, Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med. 2010;363:241623 . DOIPubMed
  25. Valenciano  M, Kissling  E, Cohen  J-M, Oroszi  B, Barret  A-S, Rizzo  C, Estimates of pandemic influenza vaccine effectiveness in Europe, 2009–2010: results of influenza monitoring vaccine effectiveness in Europe (I-MOVE) multicentre case-control study. PLoS Med. 2011;8:e1000388 . DOIPubMed
  26. Castilla  J, Morán  J, Martinez-Artola  V. Fernández -Alonso M, Guevara M, Cenoz MG, et al. Effectiveness of the monovalent influenza A(H1N1)2009 vaccine in Navarre, Spain, 2009–2010: cohort and case control study. Vaccine. 2011;29:591924. DOIPubMed
  27. Wichmann  O, Stocker  P, Poggensee  G, Altmann  D, Walter  D, Hellenbrand  W, Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009–2010. Euro Surveill. 2010;15:pii19561 .PubMed
  28. Centers for Disease Control and Prevention. Interim results: influenza A (H1N1) 2009 monovalent vaccination coverage—United States, October-December 2009. MMWR Morb Mortal Wkly Rep. 2010;59:448 .PubMed
  29. Gurav  YK, Pawar  SD, Chadha  MS, Potdar  VA, Deshpande  AS, Koratkar  SS, Pandemic influenza A(H1N1) 2009 outbreak in a residential school at Panchgani, Maharashtra, India. Indian J Med Res. 2010;132:6771 .PubMed
  30. Baker  MG, Wilson  N, Huang  QS, Paine  S, Lopez  L, Bandaranayake  D, Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009. Euro Surveill. 2009;14:pii19319 .PubMed
  31. Health Protection Agency. Pandemic (H1N1) 2009 in England: an overview of initial epidemiological findings and implications for the second wave. 2009 [cited 2011 Mar 30].
  32. von Kries  R, Weiss  S, Falkenhorst  G, Wirth  S, Kaiser  P, Huppertz  HI, Post-pandemic seroprevalence of pandemic influenza A (H1N1) 2009 infection (swine flu) among children <18 years in Germany. PLoS ONE. 2011;6:e23955 . DOIPubMed
  33. Kumar  S, Fan  J, Melzer-Lange  M, Trost  J, Havens  PL, Willoughby  RE, H1N1 hemagglutinin-inhibition seroprevalence in emergency department health care workers after the first wave of the 2009 influenza pandemic. Pediatr Emerg Care. 2011;27:8047 . DOIPubMed
  34. Jackson  ML, France  AM, Hancock  K, Lu  X, Veguilla  V, Sun  H, Serologically confirmed household transmission of 2009 pandemic influenza A (H1N1) virus during the first pandemic wave—New York City, April–May 2009. Clin Infect Dis. 2011;53:45562 . DOIPubMed
  35. Li  T, Liu  Y, Di  B, Wang  M, Shen  J, Zhang  Y, Epidemiological investigation of an outbreak of pandemic influenza A (H1N1) 2009 in a boarding school: serological analysis of 1570 cases. J Clin Virol. 2011;50:2359 . DOIPubMed
  36. Carrat  F, Vergu  E, Ferguson  NM, Lemaitre  M, Cauchemez  S, Leach  S, Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167:77585. DOIPubMed
  37. Plennevaux  E, Blatter  M, Cornish  MJ, Go  K, Kirby  D, Wali  M, Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial. Vaccine. 2011;29:156975 . DOIPubMed
  38. Stöhr  K, Esveld  M. Will vaccines be available for the next influenza pandemic? Science. 2004;306:21956. DOIPubMed
  39. Moro  PL, Broder  K, Zheteyeva  Y, Revzina  N, Tepper  N, Kissin  D, Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. Am J Obstet Gynecol. 2011;205:473.e1–9.
  40. Monto  AS, Ohmit  SE, Petrie  JG, Johnson  E, Truscon  R, Teich  E, Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009;361:12607. DOIPubMed

Main Article

1Current affiliation: Merck & Co., Inc., Lansdale, Pennsylvania, USA.

Page created: February 12, 2013
Page updated: February 12, 2013
Page reviewed: February 12, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.